Aclarion to Showcase Growth Metrics at MicroCap Conference
Event summary
- Aclarion to present at Planet MicroCap Las Vegas 2026 on June 17, 2026, with Executive Chairman Jeff Thramann leading the session.
- Company reports triple-digit annual growth in Nociscan adoption and integration into clinical workflows.
- CLARITY trial interim readout anticipated in Q4 2026, with strengthened IP footprint including 64 total issued and pending patents worldwide.
- Announced $2.5 million share repurchase program, with strong balance sheet and cash runway into second half of 2027.
The big picture
Aclarion's presentation at the Planet MicroCap conference underscores its strategic focus on scaling its Nociscan platform amid a competitive landscape in healthcare technology. The company's emphasis on clinical milestones and IP strengthening aligns with broader industry trends toward data-driven diagnostic solutions. With a strong balance sheet and accelerating adoption, Aclarion is positioning itself for long-term growth in the chronic low back pain market.
What we're watching
- Clinical Validation
- Whether the CLARITY trial interim readout in Q4 2026 will accelerate Nociscan adoption and reimbursement.
- Market Positioning
- How Aclarion's triple-digit growth and IP expansion will position it against competitors in the chronic low back pain market.
- Financial Strategy
- The pace at which the $2.5 million share repurchase program will be executed and its impact on shareholder value.
Related topics